Bibliographic record
Abstract
I n a column whose chosen focus is on 'business ' and 'health care in Canada', we would be remiss to overlook Valeant.The complex narrative of this precipitous fall is just so rich with fodder.While each step in the saga could serve as a springboard for discussion (mergers and acquisitions, short-seller attacks, senate investigations, price gouging, questionable accounting practices, hedge fund promotion, shocking market share losses, 'Cold-FX'), it really is more impressive when we run the gamut from start to present.We have been careful not to use the word 'finish'.The resolution may still be years in the making and this will certainly be out of date by the time of publication.This is a story still unfolding, and with that caveat we will do our best to sort through the themes. INCEPTION AND BACKGROUNDValeant is a Canadian company incorporated in British Columbia, headquartered in Laval, Quebec, principally run out of the United States (US), and traded on the Toronto Stock Exchange and New York Stock Exchange.The company arose from the merger of several small pharmaceutical players in the mid 1990s.Its interests are diverse: Valeant manufactures and markets a variety of over-the-counter and prescription medications across a spectrum of subspecialties and diseases.Unlike some of its pharma peers, Valeant eschews home runs for runs batted in.There are few-to-no heavy hitters in its lineup.Consistent niche players make up the team.It is not a research and development-based company; it does not devote years to developing a drug or class, bringing it to market and profiting from proprietary patented protection.Valeant is better thought of as a distributor with the catch that it is a distributor who also owns the patented rights to the medications it sells.How does it come by the product and the patent?Acquisition.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.009 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.008 | 0.005 |
| Scholarly communication | 0.010 | 0.006 |
| Open science | 0.001 | 0.002 |
| Research integrity | 0.004 | 0.008 |
| Insufficient payload (model declined to judge) | 0.026 | 0.005 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".